• GlaxoSmithKline plc, of London, and the Biomedical Advanced Research and Development Authority (BARDA) agreed to a collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism. The public-private agreement calls for the Department of Health and Human Services to provide $40 million for the initial 18-month agreement and up to $200 million if the agreement is renewed over five years. The agreement will be governed by a BARDA-GSK joint oversight committee that will monitor progress, make decisions on the allocation of funds and decide on the addition or removal of drug candidates from the portfolio.
To read more on related topics, click on one of the words below.